XM does not provide services to residents of the United States of America.

A
A

AstraZeneca

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Reuters - 2 days ago

Novo, Lilly rivals explore booming weight-loss drug market entry

CORRECTED-FACTBOX-Novo, Lilly rivals explore booming weight-loss drug market entry Corrects paragraphs 8-9 to say J&J CEO made the comments earlier this week, not in October Dec 8 (Reuters) - Novo Nordisk NOVOb.CO and Eli Lilly LLY.N have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up through acquisitions and trials.
A
N
P
R
R
Reuters - 2 days ago

US urges makers of infant RSV shots to meet winter demand

UPDATE 2-US urges makers of infant RSV shots to meet winter demand Adds details on Thermo Fisher in paragraph 7 Dec 7 (Reuters) - U.S. officials met with manufacturers of the infant and toddler RSV immunization Beyfortus this week seeking to boost access to the shot, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week .
A
S
T
Reuters - 3 days ago

US urges RSV vaccine makers to meet winter demand, White House says

US urges RSV vaccine makers to meet winter demand, White House says WASHINGTON, Dec 7 (Reuters) - U.S. officials met again with RSV vaccine manufacturers this week amid ongoing efforts to boost access to the shots, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week . The officials on Tuesday met with representatives of Sanofi SA SASY.PA , AstraZeneca AZN.L and Thermo Fisher TMO.N "and urged them to work expeditiously to me
A
S
T
Reuters - 3 days ago

AbelZeta Pharma Announces Agreement With AstraZeneca To Co-Develop A Novel Glypican 3 Armored T Therapy In China

BRIEF-AbelZeta Pharma Announces Agreement With AstraZeneca To Co-Develop A Novel Glypican 3 Armored CAR-T Therapy In China Dec 7 (Reuters) - AstraZeneca PLC AZN.L : ABELZETA PHARMA ANNOUNCES AGREEMENT WITH ASTRAZENECA TO CO-DEVELOP A NOVEL GLYPICAN 3 (GPC3) ARMORED CAR-T THERAPY IN CHINA ABELZETA PHARMA- ALSO ELIGIBLE TO RECEIVE MILESTONE PAYMENTS
A
Reuters - 3 days ago

AbbVie to buy drug developer Cerevel for $8.7 billion

UPDATE 4-AbbVie to buy drug developer Cerevel for $8.7 billion Adds details on options trading Dec 6 (Reuters) - AbbVie ABBV.N said on Wednesday it would buy Cerevel Therapeutics CERE.O , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces a raft of new competition.
A
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.